The Great Debate: AI in Rheumatology
Drs. Mrinalini Dey, Jeffrey Curtis and Jinoos Yazdany
Watch video →What's hot
View all perspectives
What's Hot
RA: Inject the Steroids
Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the 2025 ACR Convergence meeting in Chicago.
Watch video →
ACR2025 CAR-T Topic Panel
A focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping CAR-T practice right now. Panelists: Drs. Al Kim, Philip Mease, Yuz Yusof, Akhil Sood, and Jack Cush.
Watch video →
Tapering in SELECT GCA: Steroids are the Problem
Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at the 2025 ACR Convergence meeting in Chicago.
Watch video →
Specialized Biomarkers in PsA
Dr. Elaine Husni reports on abstract 0111 (Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures).
Watch video →
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
Read more →
Day 4 Recap: ACR Convergence 2025 Highlights
Join panelists Drs. Brian Jaros, Akhil Sood and Michael Putman as they recap highlights from Day 4, the final day of the 2025 ACR Convergence meeting in Chicago.
Watch video →
Weight Loss as a Therapeutic Goal in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
Read more →
ACR 2025 - Day 3 Report
Day 3 in Chicago is hump day, the last big full day of presentations and posters. The day began with an 8AM plenary session, which brings me to the first of my three notables from today:
Read more →
The Great Debate – Who Really Won?
My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.
Read more →
What's the latest in PsA?
Dr. Peter Nash highlights key studies presented at the 2025 ACR Convergence meeting.
Watch video →
Is it All About the Weight Loss?
Dr. Jeffrey Curtis discusses two abstracts about the use of GLP-1 drugs and their impact beyond weight loss.
Watch video →
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
Read more →
Secrets and Pearls in Rheumatology
Dr. Janet Pope reports on secrets and pearls in rheumatology, from a session presented at the 2025 ACR Convergence meeting in Chicago
Watch video →
Perspectives on CAR T Therapy
Dr. Philip Mease offers his perspective on and takeaways from CAR-T therapy studies presented this week at the 2025 ACR Convergence meeting in Chicago.
Watch video →
The Long View of Diagnostic Delay in Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) remains a diagnostic challenge, particularly in its early stages before structural sacroiliitis is visible on imaging.
Read more →
When the Back Hurts: uncovering BASDAI drivers in PsA
Dr. Elaine Husni reports on abstract 1426 (Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis).
Watch video →
Spondyloarthritis: The CLASSIC Study
Dr. Atul Deodhar reports on plenary session abstract 0854 (The ASAS and SPARTAN Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study).
Watch video →
Artificial intelligence isn’t a distant frontier anymore. It’s here, and it appears able to detect signs of rheumatoid arthritis, possibly before we can clinically detect it. Two studies presented at this year’s ACR meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden.
At ACR Convergence 2025, the American College of Rheumatology presents new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, antiphospholipid syndrome, and lupus.
Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.
ACR Convergence 2025 will be kicking off with a Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE), which is a great place to kick off our coverage of the meeting. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues have given data to what many of us have long suspected: a biopsy threshold of 0.5g/d of proteinuria may be too high.
Fatigue is one of the most disabling symptoms in psoriatic arthritis (PsA), yet its causes are often underexplored. At ACR 2025, Abstract #0549, a possible hidden contributor was studied: obstructive sleep apnea (OSA).
We know that pre-RA is a definition that stands under a large umbrella, ranging from asymptomatic individuals with ACPA positivity to individuals with symptomatic pre-clinical synovitis. How can we predict the transition from the at-risk state to clinical RA outside the realm of clinical, conventional serological (RF/anti-CCP) or imaging (US/MRI synovitis) biomarkers?
With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic practice.
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
Poster Hall